{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000006","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.617109+00:00","generated_at":"2026-06-07T01:01:08.239549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GoodRx pre-announces Q4 revenue above guidance; expects mid-single-digit growth in 2024","bullets":["Q4 2023 revenue and adjusted revenue expected $195-197M, up ~6-7% YoY and above prior guidance.","FY 2023 revenue expected $749-751M (-~2% YoY); adjusted revenue $759-761M (-~1% YoY).","Q4 outperformance driven by organic growth in Prescription Transactions, stronger respiratory season and favorable contracts.","Early 2024 outlook: Q1 and FY revenue and adjusted revenue to grow mid-single digits YoY; adjusted EBITDA margin in high-twenty% range.","Full Q4 and 2024 guidance to be provided on February earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000006","json":"https://secwatch.observer/filing/0001809519-24-000006.json","markdown":"https://secwatch.observer/filing/0001809519-24-000006.md","text":"https://secwatch.observer/filing/0001809519-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000006/0001809519-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000006/gdrx-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:01:08.239549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"680dbb681b5d1c9e1247aedd3c42ad83d9a83afc","claim":"GoodRx Holdings, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"GoodRx Holdings, Inc. (the “Company”) issued a press release announcing the Company’s preliminary estimates of certain financial results for the three months and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000006/0001809519-24-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}